When will generic jardiance be available?

Jardiance Patent Expiration Timeline

DrugPatentWatch.com tracks patent information for pharmaceutical products, including Jardiance (Empagliflozin). The Jardiance patent, held by Eli Lilly and Company and Boehringer Ingelheim, expires in different regions at various times.

Exclusivity Expiration Dates

In the United States, Eli Lilly's patent for Jardiance (1,2) expired in 2023. Although this marks the end of the product's exclusive marketing rights, other patents related to the formulation or production of Jardiance may still be in effect.

Generic Availability Roadmap

With the patent expiration, generic versions of Jardiance are expected to become available. According to the FDA, several generic manufacturers have filed ANDA (Abbreviated New Drug Application) submissions for Empagliflozin (3). However, the actual availability of generic Jardiance in the market will depend on the FDA's approval process and the manufacturers' production capacity.

Timeline for Generic Launch

While the exact timeline for generic Jardiance is uncertain, we can expect generic versions to enter the market in the coming years. As generic manufacturers receive FDA approval, they will begin shipping their products to distributors and pharmacies.

Regulatory Pathway for Generic Entry

According to DrugPatentWatch.com, the regulatory pathway for generic entry is as follows:

1. Generic manufacturers file ANDA submissions with the FDA.
2. The FDA reviews the submissions and may request additional information or clarification.
3. If the FDA approves the ANDA, the generic manufacturer begins production and supplies the product to the market.

Price Competition and Patient Access

As generic versions of Jardiance become available, patients may experience lower prices and improved access to the medication. Generic manufacturers often compete on price, which can lead to reduced costs and increased availability for consumers.

Sources:

[1] drugpatentwatch.com - Empagliflozin Patent Overview
[2] FDA - ANDA Approvals for Empagliflozin
[3] IQVIA - ANDA Filings for Empagliflozin